UK Markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.30-0.19 (-2.93%)
As of 4:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close6.49
Open6.58
Bid6.30 x 2900
Ask6.31 x 1800
Day's range6.14 - 6.60
52-week range6.14 - 33.79
Volume9,423,091
Avg. volume14,771,370
Market cap1.312B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)-1.07
Earnings date10 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.63
  • 1 Coronavirus Vaccine Company to Avoid Like The Plague in May (and Beyond)
    Motley Fool

    1 Coronavirus Vaccine Company to Avoid Like The Plague in May (and Beyond)

    Inovio threw its hat in the coronavirus vaccine ring as early as January 2020. The company claimed to have designed its vaccine, INO-4800, in a mere three hours after Chinese researchers publicly released the genetic sequence of the SARS-CoV-2 virus that causes the disease. Two of the most important missteps in the company's COVID-19 vaccine hunt were as follows.

  • Inovio Pharmaceuticals (INO) Q1 2021 Earnings Call Transcript
    Motley Fool

    Inovio Pharmaceuticals (INO) Q1 2021 Earnings Call Transcript

    Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO)Q1 2021 Earnings CallMay 10, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the Inovio Pharmaceuticals first-quarter 2021 financial results conference call.

  • Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

    Inovio (INO) delivered earnings and revenue surprises of -50.00% and -44.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?